Featured Research

from universities, journals, and other organizations

New Technology Detects Risks Of Drugs To Heart Sooner

Date:
May 27, 2006
Source:
University of Rochester Medical Center
Summary:
A new technology to enable pharmaceutical companies to determine more effectively, and earlier on in clinical trials, whether an experimental drug is toxic to the heart has taken an important step toward the marketplace.

A new technology to enable pharmaceutical companies to determine more effectively, and earlier on in clinical trials, whether an experimental drug is toxic to the heart has taken an important step toward the marketplace.

Related Articles


The University of Rochester Medical Center (URMC) and iCardiac Technologies, Inc. have signed an exclusive agreement to commercialize software developed by biomedical engineer Jean-Philippe Couderc, Ph.D., that provides a more accurate and reliable method to analyze data from electrocardiograms (ECG) and other types of heart monitors to determine whether a drug is toxic to the heart.

The technology consists of software known as COMPAS -- which stands for Comprehensive Analysis of Repolarization Signal -- that allows researchers to target and evaluate specific data produced by ECGs called the QT interval, in addition to other advanced measurements intended to identify specific risks associated with a new drug. The QT interval measures the process of ventricular Repolarization, the period between the heart's contraction and recovery phase. While the period lasts only a fraction of a second, it represents an important determinant of a drug's safety.

"Drug-induced prolongation of the QT interval is a critical indicator of toxicity," said Couderc. "We know that individuals with an abnormally prolonged QT interval are at far greater risk for developing fatal arrhythmias and sudden cardiac death. Consequently, effective and precise measurement of QT interval, which COMPAS provides, is an effective tool in the assessment of cardiovascular toxicity. Further, the COMPAS software will enable iCardiac Technologies to also focus on the development and deployment of additional ECG markers, which are even more specific and sensitive than traditional QT interval measurements for determining cardiac toxicity."

While there are several potential uses for this technology, the most immediate application is in clinical trials. Prolongation of the QT interval is the most common cause of drug withdrawal from the market and delays in regulatory approval. In the aftermath of the withdrawal of Vioxx and other Cox-2 inhibitor drugs over concerns that they may cause heart attacks or stroke, the FDA has proposed guidelines that call upon the pharmaceutical industry to develop better measurement methods for drug safety assessment.

In response, pharmaceutical companies are in the process of investing significant resources in research that will allow them to identify cardiac toxicity at early stages of drug testing. There is also a tremendous economic incentive: It is estimated that it costs, on average, $900 million to bring a new drug from the laboratory to the doctor's office. This new scrutiny impacts large classes of drugs, such as antibiotics, weight loss, anti-psychotic medications, heartburn medications, and some cancer and heart disease therapies, some of which have been pulled from the market or limited in use due to their tendency to prolong the QT interval.

COMPAS was designed to accurately identify ECG abnormalities, while taking into consideration other factors that may influence a person's heart activity, such as eating and stress. In fact, the FDA has purchased a license to the COMPAS software to evaluate its unique capabilities.

The new agreement pairs iCardiac Technologies -- a newly established Rochester-based company which is positioning itself as the leader in cardiac safety analytics to support pharmaceutical, biotechnology, medical device and contract research companies -- with technology developed by the University's Heart Research Follow-up Program, an international leader in cardiovascular research.

"We are extremely pleased to be working with the University of Rochester, one of the premier institutions in the world for cardiac safety," said Alex Zapesochny, president and chief operating officer of iCardiac Technologies. "The Heart Research Follow-up Program at the University of Rochester has focused on researching key challenges in this area for over 25 years and iCardiac is now positioned as a leader in this field due to the licensing of this core technology."

About iCardiac Technologies, Inc.
iCardiac Technologies, Inc., headquartered in Rochester, N.Y., is a leading provider of advanced cardiac safety analysis technologies. The company evolved from research carried out at the Heart Research Follow-up Program at the University of Rochester. The company's technology provides more rigorous characterization of the cardiac safety profiles of in-development and on-market drugs. This allows iCardiac's customers to both accelerate drug development as well as bring compounds forward in clinical trials with more confidence about their cardiac safety. Additionally, the company's core technology has applications in ECG-based cardiac diagnostics and medical devices.

About URMC's Heart Research Follow-up Program
The Heart Research Follow-up Program, which is funded in part by the National Institutes of Health, is a national and international leader in the science of heart arrhythmias and a rare genetic condition associated with an abnormal QT interval, called the congenital Long QT Syndrome (LQTS). The University keeps an International Registry for LQTS and follows thousands of families who have this inherited condition. One of the genetic forms of the QT prolongation syndrome is similar to the drug-induced syndrome, and the University's work focuses on developing the tools to identify individuals with either condition.


Story Source:

The above story is based on materials provided by University of Rochester Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Rochester Medical Center. "New Technology Detects Risks Of Drugs To Heart Sooner." ScienceDaily. ScienceDaily, 27 May 2006. <www.sciencedaily.com/releases/2006/05/060527094509.htm>.
University of Rochester Medical Center. (2006, May 27). New Technology Detects Risks Of Drugs To Heart Sooner. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2006/05/060527094509.htm
University of Rochester Medical Center. "New Technology Detects Risks Of Drugs To Heart Sooner." ScienceDaily. www.sciencedaily.com/releases/2006/05/060527094509.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Fauci Says Ebola Risk in US "essentially Zero"

Fauci Says Ebola Risk in US "essentially Zero"

AP (Oct. 30, 2014) NIAID Director Anthony Fauci said the risk of Ebola becoming an epidemic in the U.S. is essentially zero Thursday at the Washington Ideas Forum. He also said an Ebola vaccine will be tested in West Africa in the next few months. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Nurse Defies Ebola Quarantine With Bike Ride

Nurse Defies Ebola Quarantine With Bike Ride

AP (Oct. 30, 2014) A nurse who vowed to defy Maine's voluntary quarantine for health care workers who treated Ebola patients followed through on her promise Thursday, leaving her home for an hour-long bike ride. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Pot-Infused Edibles Raise Concerns in Colorado

Pot-Infused Edibles Raise Concerns in Colorado

AFP (Oct. 30, 2014) Colorado may have legalized marijuana for recreational use, but the debate around the decision still continues, with a recent - failed - attempt to ban cannabis-infused edibles. Duration: 01:53 Video provided by AFP
Powered by NewsLook.com
British Navy Ship Arrives in Sierra Leone With Ebola Aid

British Navy Ship Arrives in Sierra Leone With Ebola Aid

AFP (Oct. 30, 2014) The British ship RFA ARGUS arrived in Sierra Leone to deliver supplies and equipment to help the fight against Ebola. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins